Probiotics have garnered increasing attention as a potential therapeutic approach for type 2 diabetes mellitus (T2DM). Previous studies have confirmed that Bifidobacterium animalis subsp. lactis MN-Gup (MN-Gup) could stimulate the secretion of glucagon-like peptide-1 (GLP-1) in NCI-H716 cells, but whether MN-Gup has a hypoglycemic effect on T2DM in vivo remains unclear. In this study, a T2DM mouse model was constructed, with a high-fat diet and streptozotocin in mice, to investigate the effect of MN-Gup on diabetes. Then, different doses of MN-Gup (2 × 10⁹ CFU/kg, 1 × 10¹⁰ CFU/kg) were gavaged for 6 weeks to investigate the effect of MN-Gup on glucose metabolism and its potential mechanisms. The results showed that a high-dose of MN-Gup significantly reduced the fasting blood glucose (FBG) levels and homeostasis model assessment-insulin resistance (HOMA-IR) of T2DM mice compared to the other groups. In addition, there were significant increases in the short-chain fatty acids (SCFAs), especially acetate, and GLP-1 levels in the MN-Gup group. MN-Gup increased the relative abundance of Bifidobacterium and decreased the number of Escherichia-Shigella and Staphylococcus. Moreover, the correlation analysis revealed that Bifidobacterium demonstrated a significant positive correlation with GLP-1 and a negative correlation with the incremental AUC. In summary, this study demonstrates that Bifidobacterium animalis subsp. lactis MN-Gup has significant hypoglycemic effects in T2DM mice and can modulate the gut microbiota, promoting the secretion of SCFAs and GLP-1.

Background/Objectives: Functional constipation (FC) commonly affects middle-aged and older adults, but current pharmacological treatments have limitations. Postbiotics may offer safety advantages, but clinical evidence is limited. This randomized controlled trial evaluated the efficacy and safety of a heat-inactivated two-strain Lacticaseibacillus paracasei fermented milk in adults with FC. Methods: One hundred adults aged 45–75 years with Rome IV-defined FC received the fermented milk or placebo for 4 weeks. The primary outcome was the change in weekly spontaneous bowel movement (SBM) frequency from baseline to week 4. Secondary outcomes included complete spontaneous bowel movement (CSBM) frequency, whole-gut transit time (WGTT), constipation symptom scores, quality of life, serum biomarkers, and adverse events. Primary analysis was per-protocol (n = 96); intention-to-treat analysis was applied to primary and key secondary outcomes. Results: Dropout was 4% (n = 4, 2 per group), and adherence was >80% in both groups. The intervention showed no significant benefit over placebo for the primary outcome or for most secondary clinical outcomes. Although both groups improved within-group, no significant between-group differences were observed at week 4 for changes in SBM (MD = −0.14, 95% CI: −0.85, 0.57; p = 0.683), CSBM (MD = 0.27, 95% CI: −0.61, 1.15; p = 0.543), or WGTT (MD = −1.55 h, 95% CI: −7.65, 4.55; p = 0.614). Symptom and quality-of-life scores also did not differ between groups. Exploratory biomarker analyses showed significantly greater increases in serum VIP and ACh in the intervention group (VIP: MD = 105.23 ng/L, p < 0.001; ACh: MD = 42.95 ng/L, p = 0.035). No adverse events were reported. Conclusions: Four weeks of this postbiotic was safe but did not significantly improve bowel function or symptoms in the overall FC population. The increases in serum VIP and ACh suggest engagement of neurotransmitter-related pathways; however, these exploratory findings do not imply causation or clinical efficacy and warrant confirmation in longer-duration trials (Clinical Trial Registry: ChiCTR2500111771).

Background/objectives: The present study investigated the effect of selenium-enriched eggs (SE egg) vs. zeaxanthin-enriched eggs (ZE egg) on glycemic and lipid metabolism in patients with diabetes. Methods: Fifty-eight patients with type 2 diabetes were recruited and randomly divided into group SE egg (27 subjects) and ZE egg (31 subjects). The two groups of participants consumed either SE egg or ZE egg twice a day for a total of 12 weeks of intervention. Fasting blood samples were collected before and after the intervention to detect changes in blood glucose and lipid levels. Results: After the intervention, the fasting blood glucose, homeostatic model assessment of insulin resistance, and triglyceride-glucose index of both SE and ZE groups of subjects significantly decreased ( p < 0.05). Among subjects with a baseline glycosylated hemoglobin A1c (HbA1c) < 8.9%, eggs from both groups showed an enhanced improvement in glucose and lipid metabolism. The ZE egg group showed a significant decrease in triglycerides ( p = 0.0007) and an increase in homeostatic model assessment of β -cell function ( p = 0.06). There was no significant difference in HbA1c between the two groups after the intervention. Conclusion: This study demonstrates that SE egg and ZE eggs have comparable effects on improving glucose metabolism profiles in diabetic patients, with an improved efficacy observed in subjects with lower baseline HbA1c levels. Furthermore, ZE eggs suggest potential benefits in lowering TG levels. Clinical trial registration: https://www.chictr.org.cn/index.html , Identifer, ChiCTR2300077522.

Background/Objectives: The preschool period is critical for neurodevelopment, yet evidence investigating fortified formula’s effect and potential microbiota–gut–brain axis mechanisms in this age group is limited. To evaluate fortified formula milk’s effect on neurodevelopment and explore potential microbiota–gut–brain axis mechanisms in preschool children. Methods: In this 9-month cluster-randomized, double-blind, controlled trial, 120 healthy children aged 3–6 years from four kindergarten classes were stratified by grade and randomly allocated (1:1) to receive either multi-nutrient fortified formula (intervention, n = 60) or standard control milk (n = 60). Neurocognitive function was assessed using the Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV). Safety was evaluated through anthropometry and blood biochemistry. Gut microbiota (16S rRNA sequencing) and fecal metabolomes (untargeted LC-MS) were analyzed at baseline and 9 months. Results: The intention-to-treat (ITT) analysis showed no significant difference in Full Scale Intelligence Quotient (adjusted mean difference: 1.05 points; 95% CI: −1.42, 3.52; p = 0.400). However, the intervention group significantly improved the Processing Speed Index (adjusted mean difference: 5.91 points; 95% CI: 1.88, 9.93; p = 0.004), increased gut microbial alpha diversity (Shannon index) and Bifidobacterium abundance. Metabolomic analysis revealed elevated fecal 2-hydroxybutyric acid (2-HB), a marker of propanoate metabolism. Increases in both Bifidobacterium and 2-HB levels showed a positive association with PSI improvement (both p < 0.05). All children maintained normal growth and safety parameters. Conclusions: Fortified formula milk improved processing speed in preschoolers, a benefit associated with gut ecosystem modulation characterized by Bifidobacterium enrichment and upregulated microbial propanoate metabolism. These results offer preliminary evidence for the role of the microbiota–gut–brain axis in nutritional cognitive programming during early childhood. (Clinical Trial Registry: ChiCTR2400084211).

Background/Objectives: Fruit juice is commonly consumed with meals, yet its liquid matrix and rapidly absorbable carbohydrates may influence postprandial glycemic excursions. Whether altering the timing of fruit juice intake relative to a meal can attenuate postprandial glucose (PPG) remains unclear. This study aimed to investigate the effect of the timing of apple juice consumption on PPG in healthy adults. Methods: This randomized, two-period crossover trial (ChiCTR2600121025) enrolled 20 healthy adults in Beijing, China (March 2026), randomized 1:1; 19 with valid continuous glucose monitoring (CGM) data were analyzed. Each consumed 200 mL of 100% apple juice either 30 min before a standardized breakfast (preload) or with the same breakfast (co-ingestion), separated by a 4-day washout. Standardized lunch and dinner were provided. Blinding was not feasible. The primary outcome was breakfast peak glucose measured by CGM; secondary outcomes were incremental area under the curve (iAUC_0–210), maximum excursion, and the corresponding lunch and dinner outcomes. Results: Preloading significantly reduced breakfast peak glucose versus co-ingestion (mean difference 0.51 mmol/L; 95% confidence interval [CI] 0.07–0.94; p = 0.025) and breakfast maximum glucose excursion (0.42 mmol/L; 95% CI 0.02–0.82; p = 0.040), but not iAUC_0–210 (0.07 mmol/L·h; 95% CI −0.57 to 0.70; p = 0.830); no glycemic outcome differed at lunch or dinner. Conclusions: Consuming the same serving of apple juice 30 min before breakfast, rather than with it, reduced breakfast peak glucose and maximum glucose excursion. For individuals who already consume fruit juice, adjusting its timing relative to breakfast reduced breakfast peak glucose and maximum glucose excursion in this small sample; confirmation in larger trials is needed.

Background/Objectives: Dairy and soybean are important potential dietary sources of bone health. However, their comparative effectiveness and the role of specific components remain unclear. In this network meta-analysis (NMA), we aimed to compare the effects of various dairy and soy products (food level) and their key bioactive components (component level) on bone health in healthy women. Methods: We systematically searched PubMed, Embase, Cochrane Library, and Web of Science (up to 28 February 2025) for randomized controlled trials. A frequentist random-effects NMA was used to compare interventions for lumbar spine (LS) and total body (TB) bone mineral density (BMD) and bone turnover markers [osteocalcin (OC), deoxypyridinoline (DPD)]. Mean differences (MDs) and 95% confidence intervals were pooled. Interventions were ranked using the surface under the cumulative ranking curve (SUCRA). Results: Sixty RCTs involving 6284 participants (mean age: 54.2 years) were included. At the food level, no dairy or soy interventions significantly improved outcomes versus control, although milk + yogurt ranked numerically highest based on SUCRA values. At the bioactive-component level, the combination of casein + whey protein (MD 0.04 g/cm², 95% CI 0.01–0.06) and soybean protein (MD: 0.03 g/cm², 95% CI: 0.01–0.05) significantly increased TB BMD. Whey protein alone (SUCRA 74.4% for LS BMD) and casein + whey protein (SUCRA 86.3% for TB BMD and 75.9% for DPD) were among the highest-ranked interventions for bone health. Conclusions: The combination of milk and yogurt may be relatively promising among dairy products for bone health. Whey protein appears to be a key bioactive component beneficial for women’s bone health.